Compare IPDN & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPDN | BRTX |
|---|---|---|
| Founded | 2003 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Managed Health Care |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2M | 6.3M |
| IPO Year | 2012 | 2015 |
| Metric | IPDN | BRTX |
|---|---|---|
| Price | $1.17 | $0.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 62.0K | ★ 3.4M |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,054,219.00 | $81,000.00 |
| Revenue This Year | N/A | $438.78 |
| Revenue Next Year | N/A | $61.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.96 | $0.19 |
| 52 Week High | $12.39 | $2.04 |
| Indicator | IPDN | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.10 | 41.06 |
| Support Level | $1.10 | $0.20 |
| Resistance Level | $1.44 | $0.31 |
| Average True Range (ATR) | 0.11 | 0.03 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 17.70 | 54.65 |
Professional Diversity Network Inc is engaged in providing access to networking, training, educational and employment services to its registered users. It has three operating segments: the TalentAlly Network segment, which maintains and operates job board software and hosts career fairs; the National Association of Professional Women (NAPW) segment, which is a women-only professional networking organization; the RemoteMore segment; and Corporate Overhead. The company generates majority of its revenue from TalentAlly Network Segment.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.